Infection with the human immunodeficiency virus continues to be a leading cause of death worldwide. The current antiretroviral therapy has a number of drawbacks, including toxicity, drug-drug interactions, the development of drug resistance, the need for long-term drug therapy, poor bioavailability, and lack of access to tissues and reservoirs, even though it has significantly decreased AIDS-related morbidity and mortality. Recent anti-HIV therapeutic research has concentrated on developing drug delivery methods that are selectively targeted to host cells that are HIV-infected or at risk of becoming HIV-positive in order to get around these issues. In this context, a number of surface molecules with both viral and host cell cellular origins have been identified in recent years, which might allow for the targeted administration of drugs to HIV-infected individuals. In this review, we give a thorough overview of the need. Identifying novel viral and hostcell molecules for novel drug delivery systems, as well as the accomplishments and difficulties in doing so for targeted drug delivery of anti-HIV medications. Such customised anti-retroviral drug delivery strategies may open the door to the successful management and elimination of HIV in humans.
KeywordsHIV; Aids; Targeted Drug delivery; Viral targets; Host targets
Published Date: 2023-02-28; Received Date: 2023-02-02
